<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6790606\results\search\disease\results.xml">
  <result pre=": Review Article: Reviews Innovative strategies for the elimination of" exact="viral hepatitis" post="at a national level: A country case series SCHRÖEDER"/>
  <result pre="Review Article: Reviews Innovative strategies for the elimination of viral" exact="hepatitis" post="at a national level: A country case series SCHRÖEDER"/>
  <result pre="provided the original work is properly cited.file:LIV-39-1818.pdf Abstract Abstract Viral" exact="hepatitis" post="is a leading cause of morbidity and mortality worldwide,"/>
  <result pre="modelling studies suggest that investing in the global elimination of" exact="viral hepatitis" post="is feasible and cost�?effective. In 2016, all 194 member"/>
  <result pre="studies suggest that investing in the global elimination of viral" exact="hepatitis" post="is feasible and cost�?effective. In 2016, all 194 member"/>
  <result pre="of the World Health Organization endorsed the goal to eliminate" exact="viral hepatitis" post="as a public health threat by 2030, but complex"/>
  <result pre="the World Health Organization endorsed the goal to eliminate viral" exact="hepatitis" post="as a public health threat by 2030, but complex"/>
  <result pre="diverse range of countries that have invested in responses to" exact="viral hepatitis" post="and adopted innovative approaches to tackle their respective epidemics."/>
  <result pre="range of countries that have invested in responses to viral" exact="hepatitis" post="and adopted innovative approaches to tackle their respective epidemics."/>
  <result pre="to build a global investment case for the elimination of" exact="viral hepatitis" post="by 2030, national activities and key enablers are highlighted"/>
  <result pre="build a global investment case for the elimination of viral" exact="hepatitis" post="by 2030, national activities and key enablers are highlighted"/>
  <result pre="are highlighted that showcase the feasibility and impact of concerted" exact="hepatitis" post="responses across a range of settings, with different levels"/>
  <result pre="(a) evidence�?gathering and planning; (b) implementation; and (c) integration of" exact="viral hepatitis" post="services into the Agenda for Sustainable Development. They provide"/>
  <result pre="evidence�?gathering and planning; (b) implementation; and (c) integration of viral" exact="hepatitis" post="services into the Agenda for Sustainable Development. They provide"/>
  <result pre="facing similar challenges and resource constraints. developing countries disease elimination" exact="hepatitis" post="B hepatitis C investment case organizational case studies Funding"/>
  <result pre="challenges and resource constraints. developing countries disease elimination hepatitis B" exact="hepatitis" post="C investment case organizational case studies Funding Qatar Foundation"/>
  <result pre="PedranaA, ScottN, et al. Innovative strategies for the elimination of" exact="viral hepatitis" post="at a national level: A country case series. Liver"/>
  <result pre="ScottN, et al. Innovative strategies for the elimination of viral" exact="hepatitis" post="at a national level: A country case series. Liver"/>
  <result pre="spot GHSSH Global Health Sector Strategy on Viral Hepatitis HBIg" exact="hepatitis" post="B immunoglobulin HBsAg hepatitis B surface antigen HIV human"/>
  <result pre="Sector Strategy on Viral Hepatitis HBIg hepatitis B immunoglobulin HBsAg" exact="hepatitis" post="B surface antigen HIV human immunodeficiency virus MTCT mother�?to�?child"/>
  <result pre="Intellectual Property Rights WHO World Health Organization Key points Viral" exact="hepatitis" post="is the 6th leading cause of death globally, surpassing"/>
  <result pre="death globally, surpassing all other chronic infectious diseases including HIV," exact="tuberculosis" post="and malaria Elimination of viral hepatitis as a public"/>
  <result pre="surpassing all other chronic infectious diseases including HIV, tuberculosis and" exact="malaria" post="Elimination of viral hepatitis as a public health threat"/>
  <result pre="chronic infectious diseases including HIV, tuberculosis and malaria Elimination of" exact="viral hepatitis" post="as a public health threat is achievable; all WHO"/>
  <result pre="infectious diseases including HIV, tuberculosis and malaria Elimination of viral" exact="hepatitis" post="as a public health threat is achievable; all WHO"/>
  <result pre="in 2016 Planning, implementation and integration of national responses to" exact="viral hepatitis" post="is ongoing, and many countries have adopted innovative approaches"/>
  <result pre="2016 Planning, implementation and integration of national responses to viral" exact="hepatitis" post="is ongoing, and many countries have adopted innovative approaches"/>
  <result pre="in their local contexts Existing approaches demonstrate that investing in" exact="viral hepatitis" post="is affordable and cost�?effective, provides multisectoral cost�?benefits, and alleviates"/>
  <result pre="their local contexts Existing approaches demonstrate that investing in viral" exact="hepatitis" post="is affordable and cost�?effective, provides multisectoral cost�?benefits, and alleviates"/>
  <result pre="alleviates the human burden of the epidemic 1 INTRODUCTION Viral" exact="hepatitis" post="contributes substantially to the global burden of disease, with"/>
  <result pre="global burden of disease, with 248 million people infected with" exact="hepatitis" post="B and 71 million infected with hepatitis C worldwide.1"/>
  <result pre="people infected with hepatitis B and 71 million infected with" exact="hepatitis" post="C worldwide.1 If left untreated, chronic viral hepatitis can"/>
  <result pre="million infected with hepatitis C worldwide.1 If left untreated, chronic" exact="viral hepatitis" post="can cause life�?threatening complications, such as cirrhosis and hepatocellular"/>
  <result pre="infected with hepatitis C worldwide.1 If left untreated, chronic viral" exact="hepatitis" post="can cause life�?threatening complications, such as cirrhosis and hepatocellular"/>
  <result pre="untreated, chronic viral hepatitis can cause life�?threatening complications, such as" exact="cirrhosis" post="and hepatocellular carcinoma.2 Despite this, the public health consequences"/>
  <result pre="and hepatocellular carcinoma.2 Despite this, the public health consequences of" exact="viral hepatitis" post="have long been neglected.1 In contrast to the progress"/>
  <result pre="hepatocellular carcinoma.2 Despite this, the public health consequences of viral" exact="hepatitis" post="have long been neglected.1 In contrast to the progress"/>
  <result pre="hepatitis�?related morbidity and mortality continue to rise.1, 3 In 2010" exact="viral hepatitis" post="was the 10th leading cause of death, but by"/>
  <result pre="morbidity and mortality continue to rise.1, 3 In 2010 viral" exact="hepatitis" post="was the 10th leading cause of death, but by"/>
  <result pre="by 2015, with 1.2 million deaths, it had overtaken HIV," exact="malaria" post="and tuberculosis to rise to sixth.4 Most viral hepatitis"/>
  <result pre="with 1.2 million deaths, it had overtaken HIV, malaria and" exact="tuberculosis" post="to rise to sixth.4 Most viral hepatitis deaths are"/>
  <result pre="overtaken HIV, malaria and tuberculosis to rise to sixth.4 Most" exact="viral hepatitis" post="deaths are avertable through increased access to prevention, diagnosis"/>
  <result pre="HIV, malaria and tuberculosis to rise to sixth.4 Most viral" exact="hepatitis" post="deaths are avertable through increased access to prevention, diagnosis"/>
  <result pre="access to prevention, diagnosis and treatment. In areas of high" exact="hepatitis" post="B endemicity (eg Southeast Asia and sub�?Saharan Africa), perinatal"/>
  <result pre="procedures drive transmission elsewhere.5, 6, 7 Risk of developing chronic" exact="hepatitis" post="B infection is inversely related to age at infection:"/>
  <result pre="than 5% of persons infected as adults.8, 9, 10 The" exact="hepatitis" post="C epidemic is similarly geographically diverse and mode of"/>
  <result pre="an estimated 52% of people who inject drugs (PWID) are" exact="hepatitis" post="C antibody positive.15 Lack of access to needle and"/>
  <result pre="and treatment service coverage targets to achieve the elimination of" exact="viral hepatitis" post="as a public health threat by 2030 (defined as"/>
  <result pre="treatment service coverage targets to achieve the elimination of viral" exact="hepatitis" post="as a public health threat by 2030 (defined as"/>
  <result pre="Health Organization (WHO) targets by 2030.21, 22 Table 1 Viral" exact="hepatitis" post="service coverage and impact targets Target area Baseline 2015"/>
  <result pre="(third dose coverage) 82% of infants 90% 90% Prevention of" exact="hepatitis" post="B virus mother�?to�?child transmission: hepatitis B virus birth�?dose coverage"/>
  <result pre="infants 90% 90% Prevention of hepatitis B virus mother�?to�?child transmission:" exact="hepatitis" post="B virus birth�?dose coverage or other approach to prevent"/>
  <result pre="year for people who inject drugs 20 200 300 Viral" exact="hepatitis" post="B and C diagnosis (coverage %) &amp;lt;5% of chronic"/>
  <result pre="hepatitis B and C diagnosis (coverage %) &amp;lt;5% of chronic" exact="hepatitis" post="infections diagnosed 30% 90% Viral hepatitis B and C"/>
  <result pre="%) &amp;lt;5% of chronic hepatitis infections diagnosed 30% 90% Viral" exact="hepatitis" post="B and C treatment (coverage %) &amp;lt;1% receiving treatment"/>
  <result pre="million 80% eligible treated Impact targets Incidence: new cases of" exact="viral hepatitis" post="B and C infections Between 6 and 10 million"/>
  <result pre="80% eligible treated Impact targets Incidence: new cases of viral" exact="hepatitis" post="B and C infections Between 6 and 10 million"/>
  <result pre="reduced to 0.9 million infections by 2030 (95% declined in" exact="hepatitis" post="B virus infections, 80% decline in hepatitis C virus"/>
  <result pre="(95% declined in hepatitis B virus infections, 80% decline in" exact="hepatitis" post="C virus infections) 30% reduction (equivalent to 1% prevalence"/>
  <result pre="reduction (equivalent to 0.1% prevalence of HBsAg among children) Mortality:" exact="viral hepatitis" post="B and C deaths 1.4 million deaths reduced to"/>
  <result pre="(equivalent to 0.1% prevalence of HBsAg among children) Mortality: viral" exact="hepatitis" post="B and C deaths 1.4 million deaths reduced to"/>
  <result pre="to less than 500 000 by 2030 (65% for both" exact="viral hepatitis" post="B and C) 10% reduction 65% reduction Source: Global"/>
  <result pre="less than 500 000 by 2030 (65% for both viral" exact="hepatitis" post="B and C) 10% reduction 65% reduction Source: Global"/>
  <result pre="Hepatitis, 2016�?2021.18(C) John Wiley &amp;amp; Sons, Ltd, 1.1 How can" exact="viral hepatitis" post="be eliminated by 2030? Eliminating viral hepatitis requires substantial"/>
  <result pre="2016�?2021.18(C) John Wiley &amp;amp; Sons, Ltd, 1.1 How can viral" exact="hepatitis" post="be eliminated by 2030? Eliminating viral hepatitis requires substantial"/>
  <result pre="1.1 How can viral hepatitis be eliminated by 2030? Eliminating" exact="viral hepatitis" post="requires substantial investments in health systems strengthening and the"/>
  <result pre="How can viral hepatitis be eliminated by 2030? Eliminating viral" exact="hepatitis" post="requires substantial investments in health systems strengthening and the"/>
  <result pre="investments in health systems strengthening and the full continuum of" exact="hepatitis" post="services.18 Investing in the prevention and treatment of viral"/>
  <result pre="of hepatitis services.18 Investing in the prevention and treatment of" exact="viral hepatitis" post="provides many direct, indirect and cross�?sectoral economic benefits through"/>
  <result pre="hepatitis services.18 Investing in the prevention and treatment of viral" exact="hepatitis" post="provides many direct, indirect and cross�?sectoral economic benefits through"/>
  <result pre="in the delivery of care; and (c) integration of the" exact="viral hepatitis" post="response into SDG 3 by adopting a public health"/>
  <result pre="the delivery of care; and (c) integration of the viral" exact="hepatitis" post="response into SDG 3 by adopting a public health"/>
  <result pre="embedding services into universal health coverage.27 The necessary tools for" exact="viral hepatitis" post="elimination are already available, but worldwide implementation of a"/>
  <result pre="services into universal health coverage.27 The necessary tools for viral" exact="hepatitis" post="elimination are already available, but worldwide implementation of a"/>
  <result pre="elimination are already available, but worldwide implementation of a concerted" exact="viral hepatitis" post="response is slow and faces many challenges. These include"/>
  <result pre="are already available, but worldwide implementation of a concerted viral" exact="hepatitis" post="response is slow and faces many challenges. These include"/>
  <result pre="only 12 countries are currently on track to achieve the" exact="hepatitis" post="C elimination goal that all WHO member states adopted"/>
  <result pre="required to achieve elimination, the cost of the elimination of" exact="viral hepatitis" post="globally, and methods for countries to address existing challenges.31"/>
  <result pre="to achieve elimination, the cost of the elimination of viral" exact="hepatitis" post="globally, and methods for countries to address existing challenges.31"/>
  <result pre="Hepatitis Investment Framework highlights key enablers to support a comprehensive" exact="viral hepatitis" post="response and outlines priority national and international activities to"/>
  <result pre="Investment Framework highlights key enablers to support a comprehensive viral" exact="hepatitis" post="response and outlines priority national and international activities to"/>
  <result pre="(Table 2) that are successfully implementing innovative strategies to eliminate" exact="viral hepatitis" post="(see Table 3). Additional case studies listed in Table"/>
  <result pre="2) that are successfully implementing innovative strategies to eliminate viral" exact="hepatitis" post="(see Table 3). Additional case studies listed in Table"/>
  <result pre="S1 (Figures 2, 3, 4). Figure 1 Investment framework for" exact="viral hepatitis" post="elimination Table 2 Country characteristics Georgia South Africa Scotland"/>
  <result pre="(Figures 2, 3, 4). Figure 1 Investment framework for viral" exact="hepatitis" post="elimination Table 2 Country characteristics Georgia South Africa Scotland"/>
  <result pre="3 National activities and country examples aimed at elimination of" exact="viral hepatitis" post="National activities Country examples presented in this paper Evidence�?gathering"/>
  <result pre="National activities and country examples aimed at elimination of viral" exact="hepatitis" post="National activities Country examples presented in this paper Evidence�?gathering"/>
  <result pre="Country examples presented in this paper Evidence�?gathering and planning National" exact="hepatitis" post="plan (addressing hepatitis B, hepatitis C or both) Georgia,"/>
  <result pre="in this paper Evidence�?gathering and planning National hepatitis plan (addressing" exact="hepatitis" post="B, hepatitis C or both) Georgia, Australia, Brazil, China,"/>
  <result pre="paper Evidence�?gathering and planning National hepatitis plan (addressing hepatitis B," exact="hepatitis" post="C or both) Georgia, Australia, Brazil, China, Egypt, Iceland,"/>
  <result pre="data limit countries' capacity to guide, implement and monitor effective" exact="viral hepatitis" post="responses.32, 33 To advocate for an adequate allocation of"/>
  <result pre="limit countries' capacity to guide, implement and monitor effective viral" exact="hepatitis" post="responses.32, 33 To advocate for an adequate allocation of"/>
  <result pre="achievable targets, informed by a robust local investment case for" exact="viral hepatitis." post="Gathering accurate data to inform a targeted approach can"/>
  <result pre="launch of the GHSSH 2016�?2021, more countries have developed national" exact="hepatitis" post="plans1 and both local and global investment cases for"/>
  <result pre="both local and global investment cases for the elimination of" exact="viral hepatitis" post="have been built.31, 35, 37 Many countries have begun"/>
  <result pre="local and global investment cases for the elimination of viral" exact="hepatitis" post="have been built.31, 35, 37 Many countries have begun"/>
  <result pre="epidemiological data through national seroprevalence surveys or by adding key" exact="hepatitis" post="indicators into existing surveillance systems. Below, we give examples"/>
  <result pre="first country in the WHO European region to set a" exact="hepatitis" post="C elimination goal and develop a national plan for"/>
  <result pre="hepatitis C elimination goal and develop a national plan for" exact="viral hepatitis" post="tailored to the local context. Georgia's significant experience with"/>
  <result pre="C elimination goal and develop a national plan for viral" exact="hepatitis" post="tailored to the local context. Georgia's significant experience with"/>
  <result pre="implement large�?scale health programmes facilitated the implementation of their national" exact="hepatitis" post="C elimination programme.38 An international Technical Advisory Group assisted"/>
  <result pre="An international Technical Advisory Group assisted with describing the local" exact="hepatitis" post="C epidemiology and proposing strategies, objectives and actions to"/>
  <result pre="affordable diagnostics; providing free DAA treatment to persons with severe" exact="liver disease" post="at highest�?risk of hepatitis C�?related mortality; and building capacity"/>
  <result pre="treatment to persons with severe liver disease at highest�?risk of" exact="hepatitis" post="C�?related mortality; and building capacity to achieve programme goals"/>
  <result pre="expanded its scope to treat every person chronically infected with" exact="hepatitis" post="C, as outlined in the &quot;Strategic plan for the"/>
  <result pre="on ability to pay. Georgia is working to integrate its" exact="hepatitis" post="C elimination programme into the overall health system, because"/>
  <result pre="The implementation of the national action plan increased access to" exact="hepatitis" post="C testing and linkage to care while driving improvements"/>
  <result pre="control and prevention.38, 41 The evaluation of harm reduction�?based peer�?supported" exact="hepatitis" post="C treatment demonstrated excellent treatment uptake and retention in"/>
  <result pre="new DAAs, of whom almost 34 800 had already achieved" exact="hepatitis" post="C cure (Figure 5A). Remaining challenges relate to the"/>
  <result pre="of PWID, with stigma and discrimination preventing PWID from accessing" exact="hepatitis" post="C services. Punitive drug laws (such as criminal responsibility"/>
  <result pre="reduction programmes and lead to high rates of incarceration and" exact="hepatitis" post="C transmission in prisons, where access to OST is"/>
  <result pre="is limited. As well, as in other countries aiming for" exact="hepatitis" post="C elimination, treatment numbers declined after the first two"/>
  <result pre="of the programme, with many people being unaware of their" exact="hepatitis" post="C status or not commencing treatment. Figure 5 Timeline"/>
  <result pre="impact modelling, cost�?effectiveness analysis, and fiscal space analysis for scaled�?up" exact="hepatitis" post="B and hepatitis C disease control scenarios.35 The action"/>
  <result pre="analysis, and fiscal space analysis for scaled�?up hepatitis B and" exact="hepatitis" post="C disease control scenarios.35 The action plan was developed"/>
  <result pre="and affordability, health impact and cost�?effectiveness for four priority interventions:" exact="hepatitis" post="B birth dose vaccination, prevention of MTCT and treatment"/>
  <result pre="B birth dose vaccination, prevention of MTCT and treatment for" exact="hepatitis" post="B and C. The model suggests expanded hepatitis B"/>
  <result pre="treatment for hepatitis B and C. The model suggests expanded" exact="hepatitis" post="B prevention and treatment for hepatitis B and C"/>
  <result pre="The model suggests expanded hepatitis B prevention and treatment for" exact="hepatitis" post="B and C (using DAAs for the latter) is"/>
  <result pre="cost�?effective and affordable in the South African context,35 noting that" exact="hepatitis" post="B birth dose vaccination should be prioritised if funds"/>
  <result pre="the initial five�?year investment could avert an estimated 13 000" exact="hepatitis" post="B�?related deaths and 7000 hepatitis C�?related deaths. Moreover, a"/>
  <result pre="avert an estimated 13 000 hepatitis B�?related deaths and 7000" exact="hepatitis" post="C�?related deaths. Moreover, a continued expansion of the treatment"/>
  <result pre="programme beyond 2021 has the potential to avert 672 000" exact="hepatitis" post="B�?infections and 60 000 deaths averted from hepatitis C�?related"/>
  <result pre="672 000 hepatitis B�?infections and 60 000 deaths averted from" exact="hepatitis" post="C�?related liver disease, which would put South Africa firmly"/>
  <result pre="hepatitis B�?infections and 60 000 deaths averted from hepatitis C�?related" exact="liver disease," post="which would put South Africa firmly on the path"/>
  <result pre="develop an investment case for the cost�?effectiveness and affordability of" exact="hepatitis" post="control and elimination for South Africa provides a template"/>
  <result pre="2019, with five priority interventions during the first year: (a)" exact="hepatitis" post="B birth dose vaccination; (b) healthcare worker hepatitis screening,"/>
  <result pre="year: (a) hepatitis B birth dose vaccination; (b) healthcare worker" exact="hepatitis" post="screening, vaccination and training in viral hepatitis (c) increasing"/>
  <result pre="vaccination; (b) healthcare worker hepatitis screening, vaccination and training in" exact="viral hepatitis" post="(c) increasing awareness, diagnosis and management of Hepatitis B"/>
  <result pre="(b) healthcare worker hepatitis screening, vaccination and training in viral" exact="hepatitis" post="(c) increasing awareness, diagnosis and management of Hepatitis B"/>
  <result pre="of DAAs and price negotiations; (e) a comprehensive package of" exact="viral hepatitis" post="services for key populations – men who have sex"/>
  <result pre="DAAs and price negotiations; (e) a comprehensive package of viral" exact="hepatitis" post="services for key populations – men who have sex"/>
  <result pre="a shortage of trained health workers; lack of knowledge about" exact="viral hepatitis" post="in the general public; viral hepatitis�?related stigma; limited access"/>
  <result pre="shortage of trained health workers; lack of knowledge about viral" exact="hepatitis" post="in the general public; viral hepatitis�?related stigma; limited access"/>
  <result pre="and punitive drug laws. There is a need to improve" exact="viral hepatitis" post="services in other key populations, including prisoners, sex workers"/>
  <result pre="punitive drug laws. There is a need to improve viral" exact="hepatitis" post="services in other key populations, including prisoners, sex workers"/>
  <result pre="at the South African Health Products Regulatory Authority, preventing broader" exact="hepatitis" post="C treatment scale�?up. In order to address these obstacles,"/>
  <result pre="Group has established three subcommittees to oversee implementation of the" exact="hepatitis" post="B birth dose vaccine, training of healthcare workers in"/>
  <result pre="in conjunction with training on new HIV treatment regimens, and" exact="hepatitis" post="C micro�?elimination programmes. 1.5 Scotland: accurate data to inform"/>
  <result pre="scientific evidence to raise awareness of the human impact of" exact="hepatitis" post="C and its links to inequalities, which generated political"/>
  <result pre="(DBS) sampling in community drug services made the model of" exact="viral hepatitis" post="care more acceptable to affected communities and helped overcome"/>
  <result pre="sampling in community drug services made the model of viral" exact="hepatitis" post="care more acceptable to affected communities and helped overcome"/>
  <result pre="evidence to inform and generate proposals for the development of" exact="hepatitis" post="C services and identify the additional investment required. Subsequently,"/>
  <result pre="services and deliver evidence�?based actions throughout the country for improved" exact="hepatitis" post="C prevention and control (Figure 5C). Since 2011, the"/>
  <result pre="diagnosis and treatment services led to a significant decline in" exact="hepatitis" post="C incidence, more new diagnoses, more people undergoing hepatitis"/>
  <result pre="in hepatitis C incidence, more new diagnoses, more people undergoing" exact="hepatitis" post="C treatment and achieving cure, reductions in liver�?related morbidity"/>
  <result pre="morbidity and mortality, and a decreased population prevalence of chronic" exact="hepatitis" post="C.47, 50, 51, 52 Scotland's example showcases the utility"/>
  <result pre="51, 52 Scotland's example showcases the utility of evidence�?based national" exact="hepatitis" post="C strategies in reducing the financial and societal burden"/>
  <result pre="Scotland during the era of interferon�?based treatment, the prevalence of" exact="hepatitis" post="C infection had remained stubbornly high. The recent scale�?up"/>
  <result pre="1.6 Implementation Globally, nine of the 10 people living with" exact="viral hepatitis" post="are unaware of their infection,33 and lack of public"/>
  <result pre="Implementation Globally, nine of the 10 people living with viral" exact="hepatitis" post="are unaware of their infection,33 and lack of public"/>
  <result pre="compounded by viral hepatitis�?related stigma and discrimination. Implementation of a" exact="viral hepatitis" post="strategy should therefore include awareness�?raising activities to generate demand"/>
  <result pre="by viral hepatitis�?related stigma and discrimination. Implementation of a viral" exact="hepatitis" post="strategy should therefore include awareness�?raising activities to generate demand"/>
  <result pre="strategy should therefore include awareness�?raising activities to generate demand for" exact="viral hepatitis" post="care (eg through social media campaigns, such as in"/>
  <result pre="should therefore include awareness�?raising activities to generate demand for viral" exact="hepatitis" post="care (eg through social media campaigns, such as in"/>
  <result pre="activities should be implemented and scaled up to effectively eliminate" exact="viral hepatitis" post="transmission. A highly effective hepatitis B vaccine has been"/>
  <result pre="should be implemented and scaled up to effectively eliminate viral" exact="hepatitis" post="transmission. A highly effective hepatitis B vaccine has been"/>
  <result pre="up to effectively eliminate viral hepatitis transmission. A highly effective" exact="hepatitis" post="B vaccine has been available since the 1980s, and"/>
  <result pre="since the 1980s, and early immunisation plus the distribution of" exact="hepatitis" post="B immunoglobulin (HBIg) to at�?risk infants prevents perinatal transmission,"/>
  <result pre="contributing to health systems strengthening.4, 64 Finally, implementation of a" exact="viral hepatitis" post="response must aim to optimise the viral hepatitis care"/>
  <result pre="to health systems strengthening.4, 64 Finally, implementation of a viral" exact="hepatitis" post="response must aim to optimise the viral hepatitis care"/>
  <result pre="of a viral hepatitis response must aim to optimise the" exact="viral hepatitis" post="care cascade by substantially improving testing rates, linkage to"/>
  <result pre="a viral hepatitis response must aim to optimise the viral" exact="hepatitis" post="care cascade by substantially improving testing rates, linkage to"/>
  <result pre="and civil society engagement.67 It has championed the cause of" exact="viral hepatitis" post="and advocated for an intensified global response for many"/>
  <result pre="civil society engagement.67 It has championed the cause of viral" exact="hepatitis" post="and advocated for an intensified global response for many"/>
  <result pre="the trend of the HIV epidemic, Brazil established a national" exact="hepatitis" post="programme informed by up�?to�?date estimates of disease prevalence, international"/>
  <result pre="in the Brazilian Unified Health System.57 Brazil invested in universal" exact="hepatitis" post="B vaccination, increased capacity for hepatitis C testing in"/>
  <result pre="Brazil invested in universal hepatitis B vaccination, increased capacity for" exact="hepatitis" post="C testing in HIV services, expanded its laboratory network"/>
  <result pre="its laboratory network and set up a referral system for" exact="hepatitis" post="patients. To reach the target population, the Ministry of"/>
  <result pre="these goals by 2030.57 Brazil has pledged to provide free" exact="hepatitis" post="C treatment to everyone infected and is one of"/>
  <result pre="and is one of 12 countries on track to achieve" exact="hepatitis" post="C elimination by 2030 (Figure 6A).30 Figure 6 Timeline"/>
  <result pre="home to nearly one third of all people living with" exact="hepatitis" post="B infection globally. HBsAg prevalence is estimated at 5.5%2"/>
  <result pre="B infection globally. HBsAg prevalence is estimated at 5.5%2 and" exact="hepatitis" post="B causes over 300 000 deaths annually due to"/>
  <result pre="annually due to liver diseases.69 The implementation of a universal" exact="hepatitis" post="B vaccination programme for infants has reduced chronic hepatitis"/>
  <result pre="universal hepatitis B vaccination programme for infants has reduced chronic" exact="hepatitis" post="B incidence dramatically during the past two decades. The"/>
  <result pre="supply of HBIg for at�?risk newborns. Domestic procurement of the" exact="hepatitis" post="B vaccine and auto�?disable syringes ensures sustainable supply chains"/>
  <result pre="including an investment of ~ USD76 million to subsidise the" exact="hepatitis" post="B catch�?up vaccination programme for 15 million children through"/>
  <result pre="(Figure 6B). As a result, &amp;gt;95% of infants receive the" exact="hepatitis" post="B vaccine within 24 hours of birth.72, 73, 74,"/>
  <result pre="2013, China's efforts have prevented 90 million cases of chronic" exact="hepatitis" post="B infection and 24 million fewer people are carriers"/>
  <result pre="of viral hepatitis.70 Although China has made considerable progress with" exact="hepatitis" post="B, systemic obstacles to the elimination of MTCT remain."/>
  <result pre="physicians trained to provide treatment (ie obstetricians, gynaecologists, gastroenterologists and" exact="infectious disease" post="specialists working in central hospitals) are often reluctant to"/>
  <result pre="is yet to implement a comprehensive national strategy addressing its" exact="hepatitis" post="C epidemic. Few DAAs have been approved and their"/>
  <result pre="care and treatment Egypt has a very high burden of" exact="hepatitis" post="C infection and disease, with approximately 7% of Egyptians"/>
  <result pre="with approximately 7% of Egyptians aged 18�?59 living with chronic" exact="hepatitis" post="C infection in 2015.76 This large reservoir of active"/>
  <result pre="were newly infected.77 Egypt is committed to ending its generalised" exact="hepatitis" post="C epidemic. It has developed one of the largest"/>
  <result pre="It has developed one of the largest national programmes for" exact="hepatitis" post="C treatment.78 Egypt provides free and universal access to"/>
  <result pre="a national action plan for the prevention and control of" exact="viral hepatitis." post="To maximise efficiencies, the country has rolled out mass"/>
  <result pre="out mass screening since October 2018, providing direct linkage to" exact="hepatitis" post="C care. Over six months, more than 49 million"/>
  <result pre="were reached, of whom over 2 million were diagnosed as" exact="hepatitis" post="C�?antibody positive (in addition, &amp;gt;2.5 million possible cases of"/>
  <result pre="were identified and referred for further assessment and management). Of" exact="hepatitis" post="C patients linked to care and confirmed as ribonucleic"/>
  <result pre="to achieve WHO elimination targets in spite of its high" exact="hepatitis" post="C prevalence (Figure 6C).78, 79 Egypt's response was facilitated"/>
  <result pre="Finally, plans and strategies for surveillance to reliably capture whether" exact="hepatitis" post="C elimination targets have been met are not fully"/>
  <result pre="are not fully developed. 1.10 Integration The cost burden of" exact="viral hepatitis" post="diagnostic tests and treatment – in particular the new"/>
  <result pre="not fully developed. 1.10 Integration The cost burden of viral" exact="hepatitis" post="diagnostic tests and treatment – in particular the new"/>
  <result pre="and treatment – in particular the new DAA treatment for" exact="hepatitis" post="C – challenges the feasibility and sustainability of effective"/>
  <result pre="hepatitis C – challenges the feasibility and sustainability of effective" exact="viral hepatitis" post="elimination activities. Unlike for other major communicable diseases such"/>
  <result pre="C – challenges the feasibility and sustainability of effective viral" exact="hepatitis" post="elimination activities. Unlike for other major communicable diseases such"/>
  <result pre="activities. Unlike for other major communicable diseases such as HIV," exact="tuberculosis" post="and malaria, there is little funding available for viral"/>
  <result pre="HIV, tuberculosis and malaria, there is little funding available for" exact="viral hepatitis" post="at an international level and most countries lack dedicated"/>
  <result pre="tuberculosis and malaria, there is little funding available for viral" exact="hepatitis" post="at an international level and most countries lack dedicated"/>
  <result pre="hepatitis at an international level and most countries lack dedicated" exact="hepatitis" post="budgets or programmes.18 Although the private sector (such as"/>
  <result pre="mobilised from public, domestic sources to ensure the sustainability of" exact="viral hepatitis" post="services as part of a broader effort to increase"/>
  <result pre="from public, domestic sources to ensure the sustainability of viral" exact="hepatitis" post="services as part of a broader effort to increase"/>
  <result pre="health systems strengthening) is not only a key enabler for" exact="viral hepatitis" post="elimination but a requirement to reach the overarching SDG"/>
  <result pre="systems strengthening) is not only a key enabler for viral" exact="hepatitis" post="elimination but a requirement to reach the overarching SDG"/>
  <result pre="health and its target of universal health coverage.19 Ensuring that" exact="hepatitis" post="services are integrated within these systems can reduce costs,"/>
  <result pre="access to services for key risk populations.83 For example conducting" exact="viral hepatitis" post="testing at HIV services is likely to yield high"/>
  <result pre="to services for key risk populations.83 For example conducting viral" exact="hepatitis" post="testing at HIV services is likely to yield high"/>
  <result pre="because people living with HIV have a higher risk of" exact="hepatitis" post="B or hepatitis C co�?infection, and may improve their"/>
  <result pre="with HIV have a higher risk of hepatitis B or" exact="hepatitis" post="C co�?infection, and may improve their engagement in care.84"/>
  <result pre="into HIV programmes, because further opportunities exist to broaden the" exact="viral hepatitis" post="response by integrating it within tuberculosis, maternal and child"/>
  <result pre="HIV programmes, because further opportunities exist to broaden the viral" exact="hepatitis" post="response by integrating it within tuberculosis, maternal and child"/>
  <result pre="activity. For example, additional time is needed to administer a" exact="hepatitis" post="B vaccine or to provide post�?test counselling for positive"/>
  <result pre="to concerns about extra costs and workload, efforts to integrate" exact="viral hepatitis" post="responses into existing systems and platforms may receive substantial"/>
  <result pre="concerns about extra costs and workload, efforts to integrate viral" exact="hepatitis" post="responses into existing systems and platforms may receive substantial"/>
  <result pre="there is no evidence to support the notion that introducing" exact="viral hepatitis" post="care into these systems causes existing structures to collapse.85"/>
  <result pre="is no evidence to support the notion that introducing viral" exact="hepatitis" post="care into these systems causes existing structures to collapse.85"/>
  <result pre="Table 4 Hepatitis B vaccination coverage and procurement status of" exact="hepatitis" post="C medicines Country Hepatitis B vaccination coverage (2019)75 Hepatitis"/>
  <result pre="South Africa 74%2 n/a Yes VL No No aEstimates of" exact="hepatitis" post="B vaccination coverage were produced only for countries with"/>
  <result pre="low�?income country that is using a public health framework for" exact="hepatitis" post="control and care to progress on its aim to"/>
  <result pre="has made tremendous gains in maternal and child health, malaria," exact="tuberculosis" post="and HIV outcomes. The Rwandan Government now invests major"/>
  <result pre="HIV outcomes. The Rwandan Government now invests major resources in" exact="viral hepatitis," post="using programmatic steps that form a blueprint for other"/>
  <result pre="countries in the region.88 Key elements of Rwanda's programme for" exact="viral hepatitis" post="prevention and treatment include: Simplified treatment algorithms not requiring"/>
  <result pre="in the region.88 Key elements of Rwanda's programme for viral" exact="hepatitis" post="prevention and treatment include: Simplified treatment algorithms not requiring"/>
  <result pre="hepatitis prevention and treatment include: Simplified treatment algorithms not requiring" exact="hepatitis" post="C genotype or hepatitis B viral load and largely"/>
  <result pre="include: Simplified treatment algorithms not requiring hepatitis C genotype or" exact="hepatitis" post="B viral load and largely able to be delivered"/>
  <result pre="staff Development, funding and implementation of birth dose vaccination for" exact="hepatitis" post="B. To ascertain feasibility and ensure financing for sustainability,"/>
  <result pre="levels of coverage of screening, diagnosis, and treatment of both" exact="hepatitis" post="B and C.88 Several initiatives were used to secure"/>
  <result pre="560 in 2017).66, 88 Rwanda's Essential Medicines List includes generic" exact="hepatitis" post="B medicines treatment; this is subsidised by government for"/>
  <result pre="the cost. Ultimately, the aim is to provide reimbursement for" exact="hepatitis" post="C diagnostics and treatment by the community�?based health insurance"/>
  <result pre="Rwanda (A) and Australia (B) Major ongoing barriers to addressing" exact="viral hepatitis" post="in Rwanda include the lower awareness of, and priority"/>
  <result pre="(A) and Australia (B) Major ongoing barriers to addressing viral" exact="hepatitis" post="in Rwanda include the lower awareness of, and priority"/>
  <result pre="Rwanda include the lower awareness of, and priority given to," exact="viral hepatitis" post="compared to other infectious diseases (eg malaria and HIV)"/>
  <result pre="include the lower awareness of, and priority given to, viral" exact="hepatitis" post="compared to other infectious diseases (eg malaria and HIV)"/>
  <result pre="given to, viral hepatitis compared to other infectious diseases (eg" exact="malaria" post="and HIV) and the competing priorities for limited public�?sector"/>
  <result pre="failed and has since been abandoned was to develop local" exact="viral hepatitis" post="treatment guidelines based upon international consensus guidelines, without sufficient"/>
  <result pre="and has since been abandoned was to develop local viral" exact="hepatitis" post="treatment guidelines based upon international consensus guidelines, without sufficient"/>
  <result pre="the first countries to implement and subsequently refine their national" exact="hepatitis" post="C strategies and has since then become a best"/>
  <result pre="and has since then become a best practice model for" exact="hepatitis" post="C elimination. Key to Australia's response, including achieving universal"/>
  <result pre="for treatment, such as PWID and prisoners, necessary to achieve" exact="hepatitis" post="C elimination. In addition, all registered medical practitioners are"/>
  <result pre="patient�?centred care. In Australia, close collaboration between people living with" exact="hepatitis" post="C, community organisations, clinicians and policymakers facilitated improved access"/>
  <result pre="Australia aims to treat around 15 000 to 20 000" exact="hepatitis" post="C patients per year, to reach the WHO target"/>
  <result pre="patients per year, to reach the WHO target to eliminate" exact="viral hepatitis" post="as a major public health threat by 2030. This"/>
  <result pre="per year, to reach the WHO target to eliminate viral" exact="hepatitis" post="as a major public health threat by 2030. This"/>
  <result pre="39% in June 2017.93 With the successful implementation of its" exact="hepatitis" post="C strategy – a global benchmark for best practice94"/>
  <result pre="DISCUSSION The broader benefits of investing in the elimination of" exact="viral hepatitis" post="– including progressing on the SDGs �? are increasingly"/>
  <result pre="The broader benefits of investing in the elimination of viral" exact="hepatitis" post="– including progressing on the SDGs �? are increasingly"/>
  <result pre="environments are effectively responding to their respective epidemics. Attaining the" exact="viral hepatitis" post="elimination targets set by the global community in 2016"/>
  <result pre="are effectively responding to their respective epidemics. Attaining the viral" exact="hepatitis" post="elimination targets set by the global community in 2016"/>
  <result pre="and maintain national elimination efforts. Gathering sufficient funds to finance" exact="viral hepatitis" post="programmes continues to be difficult among competing health priorities"/>
  <result pre="maintain national elimination efforts. Gathering sufficient funds to finance viral" exact="hepatitis" post="programmes continues to be difficult among competing health priorities"/>
  <result pre="example, in Egypt expenditure on diagnostics now exceeds that on" exact="hepatitis" post="C treatment.68 There are few WHO prequalified point�?of�?care viral"/>
  <result pre="on hepatitis C treatment.68 There are few WHO prequalified point�?of�?care" exact="viral hepatitis" post="tests and little production of low�?cost high�?quality generic tests."/>
  <result pre="hepatitis C treatment.68 There are few WHO prequalified point�?of�?care viral" exact="hepatitis" post="tests and little production of low�?cost high�?quality generic tests."/>
  <result pre="procurement systems for essential medicines is an ongoing challenge. For" exact="hepatitis" post="B, cold chain barriers to vaccination including birth dose"/>
  <result pre="a challenge globally; meanwhile, in countries where scale�?up of a" exact="viral hepatitis" post="response is pending, demand for viral hepatitis testing and"/>
  <result pre="challenge globally; meanwhile, in countries where scale�?up of a viral" exact="hepatitis" post="response is pending, demand for viral hepatitis testing and"/>
  <result pre="scale�?up of a viral hepatitis response is pending, demand for" exact="viral hepatitis" post="testing and treatment can outstrip available testing and treatment"/>
  <result pre="of a viral hepatitis response is pending, demand for viral" exact="hepatitis" post="testing and treatment can outstrip available testing and treatment"/>
  <result pre="impediments imposed on key populations at risk or infected with" exact="viral hepatitis" post="(eg PWID, prisoners, men who have sex with men,"/>
  <result pre="imposed on key populations at risk or infected with viral" exact="hepatitis" post="(eg PWID, prisoners, men who have sex with men,"/>
  <result pre="screening efforts in Egypt and using innovative approaches to increase" exact="hepatitis" post="C testing in Scotland, to building local investment cases"/>
  <result pre="to building local investment cases in South Africa, to integrating" exact="viral hepatitis" post="services into existing health infrastructure in Brazil and Rwanda,"/>
  <result pre="building local investment cases in South Africa, to integrating viral" exact="hepatitis" post="services into existing health infrastructure in Brazil and Rwanda,"/>
  <result pre="99) can help persuade policymakers in other countries to support" exact="viral hepatitis" post="prevention and control plans. In�?country and global advocacy must"/>
  <result pre="can help persuade policymakers in other countries to support viral" exact="hepatitis" post="prevention and control plans. In�?country and global advocacy must"/>
  <result pre="plans. In�?country and global advocacy must be maintained to keep" exact="viral hepatitis" post="high on the political agenda.82 3 CONCLUSION At the"/>
  <result pre="In�?country and global advocacy must be maintained to keep viral" exact="hepatitis" post="high on the political agenda.82 3 CONCLUSION At the"/>
  <result pre="the global community uniformly endorsed the unique opportunity to eliminate" exact="viral hepatitis" post="as a public health threat. Although an ambitious goal,"/>
  <result pre="global community uniformly endorsed the unique opportunity to eliminate viral" exact="hepatitis" post="as a public health threat. Although an ambitious goal,"/>
  <result pre="and increasing recognition of the public health threat posed by" exact="viral hepatitis" post="provides the grounds for substantial political and societal support."/>
  <result pre="increasing recognition of the public health threat posed by viral" exact="hepatitis" post="provides the grounds for substantial political and societal support."/>
  <result pre="support. The broader benefits of investing in the elimination of" exact="viral hepatitis" post="– including progress on the Agenda for Sustainable Development"/>
  <result pre="The broader benefits of investing in the elimination of viral" exact="hepatitis" post="– including progress on the Agenda for Sustainable Development"/>
  <result pre="countries will need to take action if global elimination of" exact="viral hepatitis" post="is to be achieved. Looking to existing approaches that"/>
  <result pre="will need to take action if global elimination of viral" exact="hepatitis" post="is to be achieved. Looking to existing approaches that"/>
  <result pre="is to be achieved. Looking to existing approaches that address" exact="viral hepatitis" post="can facilitate political support, because they demonstrate that investing"/>
  <result pre="to be achieved. Looking to existing approaches that address viral" exact="hepatitis" post="can facilitate political support, because they demonstrate that investing"/>
  <result pre="can facilitate political support, because they demonstrate that investing in" exact="viral hepatitis" post="is cost�?effective and can be made affordable, provide multiple"/>
  <result pre="facilitate political support, because they demonstrate that investing in viral" exact="hepatitis" post="is cost�?effective and can be made affordable, provide multiple"/>
  <result pre="by low�?, middle�? and high�?income countries with diverse epidemics of" exact="hepatitis" post="B and C to achieve the WHO 2030 viral"/>
  <result pre="of hepatitis B and C to achieve the WHO 2030" exact="viral hepatitis" post="elimination targets. CONFLICT OF INTEREST AHS reports grants and"/>
  <result pre="hepatitis B and C to achieve the WHO 2030 viral" exact="hepatitis" post="elimination targets. CONFLICT OF INTEREST AHS reports grants and"/>
  <result pre="HornJ, MikolajczykRT, KrauseG, OttJJ. Estimations of worldwide prevalence of chronic" exact="hepatitis" post="B virus infection: a systematic review of data published"/>
  <result pre="from: http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionxml:id=9DECA1FF83BC4A8C41B74E3BE2649662?sequence=1. 5EdmundsWJ, MedleyGF, NokesDJ, et al. Epidemiological patterns of" exact="hepatitis" post="B virus (HBV) in highly endemic areas. Epidemiol Infect."/>
  <result pre="areas. Epidemiol Infect. 1996;117:313�?325.8870629 6KiireCF. The epidemiology and prophylaxis of" exact="hepatitis" post="B in sub�?Saharan Africa: a view from tropical and"/>
  <result pre="2):S5�?S12.8786055 7CornbergM, RazaviHA, AlbertiA, et al. A systematic review of" exact="hepatitis" post="C virus epidemiology in Europe, Canada and Israel. Liver"/>
  <result pre="Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. 9OttJJ, StevensGA, GroegerJ, WiersmaST. Global epidemiology of" exact="hepatitis" post="B virus infection: new estimates of age�?specific HBsAg seroprevalence"/>
  <result pre="and endemicity. Vaccine. 2012;30:2212�?2219.22273662 10HyamsKC. Risks of chronicity following acute" exact="hepatitis" post="B virus infection: a review. Clin Infect Dis. 1995;20:992�?1000.7795104"/>
  <result pre="Dis. 1995;20:992�?1000.7795104 11BruggmannP, BergT, OvrehusAL, et al. Historical epidemiology of" exact="hepatitis" post="C virus (HCV) in selected countries. J Viral Hepat."/>
  <result pre="2014;21(Suppl 1):5�?33.24713004 12LiakinaV, HamidS, TanakaJ, et al. Historical epidemiology of" exact="hepatitis" post="C virus (HCV) in select countries �? volume 3."/>
  <result pre="2015;22(Suppl 4):4�?20.26513445 13MaaroufiA, VinceA, HimattSM, et al. Historical epidemiology of" exact="hepatitis" post="C virus in select countries�?volume 4. J Viral Hepat."/>
  <result pre="2):8�?24.29105285 14SaraswatV, NorrisS, de KnegtRJ, et al. Historical epidemiology of" exact="hepatitis" post="C virus (HCV) in select countries �? volume 2."/>
  <result pre="to injecting drug use as a risk factor for HIV," exact="hepatitis" post="C, and hepatitis B: findings from the Global Burden"/>
  <result pre="use as a risk factor for HIV, hepatitis C, and" exact="hepatitis" post="B: findings from the Global Burden of Disease Study"/>
  <result pre="26, 2017. 20HutinYJ�?F, BulterysM, HirnschallGO. How far are we from" exact="viral hepatitis" post="elimination service coverage targets?J Int AIDS Soc. 2018;21:e25050.29633520 21HeffernanA,"/>
  <result pre="2017. 20HutinYJ�?F, BulterysM, HirnschallGO. How far are we from viral" exact="hepatitis" post="elimination service coverage targets?J Int AIDS Soc. 2018;21:e25050.29633520 21HeffernanA,"/>
  <result pre="HallettTB. Scaling up prevention and treatment towards the elimination of" exact="hepatitis" post="C: a global mathematical model. Lancet. 2019;393(10178):1319�?1329.30704789 22NayagamS, ThurszM,"/>
  <result pre="22NayagamS, ThurszM, SicuriE, et al. Requirements for global elimination of" exact="hepatitis" post="B: a modelling study. Lancet Infect Dis. 2016;16:1399�?1408.27638356 23ScottN,"/>
  <result pre="Hepatol. 2018;16:1641�?1649.e629505905 25YounossiZ, BrownA, ButiM, et al. Impact of eradicating" exact="hepatitis" post="C virus on the work productivity of chronic hepatitis"/>
  <result pre="eradicating hepatitis C virus on the work productivity of chronic" exact="hepatitis" post="C (CH�?C) patients: an economic model from five European"/>
  <result pre="26DiBonaventuraMD, WagnerJ�?S, YuanY, L'ItalienG, LangleyP, Ray KimW. The impact of" exact="hepatitis" post="C on labor force participation, absenteeism, presenteeism and non�?work"/>
  <result pre="World Bank; 2017. Licence: CC BY-NC-SA 3.0 IGO. 28FitzsimonsD. A" exact="viral hepatitis" post="free future: how to make it feasible and affordable"/>
  <result pre="Bank; 2017. Licence: CC BY-NC-SA 3.0 IGO. 28FitzsimonsD. A viral" exact="hepatitis" post="free future: how to make it feasible and affordable"/>
  <result pre="5–6. 29collab: Viral Hepatitis Prevention Board . Innovative financing into" exact="hepatitis" post="B and C prevention and treatment in low and"/>
  <result pre="Foundation . Just 12 countries worldwide on track to eliminate" exact="hepatitis" post="C infection by 2030, with United Kingdom, Italy and"/>
  <result pre="32collab: World Health Organization . Global health sector strategy on" exact="viral hepatitis" post="2016–2021 In: collab: HIV/AIDS Do , ed. Towards ending"/>
  <result pre="World Health Organization . Global health sector strategy on viral" exact="hepatitis" post="2016–2021 In: collab: HIV/AIDS Do , ed. Towards ending"/>
  <result pre="hepatitis 2016–2021 In: collab: HIV/AIDS Do , ed. Towards ending" exact="viral hepatitis." post="Geneva, Switzerland: WHO Document Production Services; 2016. 33collab: World"/>
  <result pre="Accessed January 16, 2019. 34ScottN, StoovéM, WilsonDP, et al. Eliminating" exact="hepatitis" post="C virus as a public health threat among HIV�?positive"/>
  <result pre="2018;21:e25059. 35HechtR, HiebertL, SpearmanWC, et al. The investment case for" exact="hepatitis" post="B and C in South Africa: adaptation and innovation"/>
  <result pre="36LazarusJ, Safreed�?HarmonK, ThurszM, et al. The micro�?elimination approach to eliminating" exact="hepatitis" post="C: strategic and operational considerations. Semin Liver Dis. 2018;38:181�?192.29986353"/>
  <result pre="Hepatol. 2016;64:S469. 38GvinjiliaL, NasrullahM, SergeenkoD, et al. National progress toward" exact="hepatitis" post="c elimination �? Georgia, 2015–2016. MMWR Morb Mortal Wkly"/>
  <result pre="PLoS ONE. 2019;14:e0216123.31034530 41collab: World Health Organization Europe . Georgia's" exact="hepatitis" post="C elimination programme setting an example in Europe. Health"/>
  <result pre="http://www.euro.who.int/en/health-topics/communicable-diseases/pages/news/news/2017/08/georgias-hepatitis-c-elimination-programme-setting-an-example-in-europe. 42KikvidzeT, LuhmannN, AvrilE, et al. Harm reduction�?based and peer�?supported" exact="hepatitis" post="C treatment for people who inject drugs in Georgia."/>
  <result pre="52HutchinsonS, ValerioH, DillonJ, et al. Reduction in the incidence of" exact="hepatitis" post="C�?related decompensated cirrhosis associated with national scale�?up of direct�?acting"/>
  <result pre="et al. Reduction in the incidence of hepatitis C�?related decompensated" exact="cirrhosis" post="associated with national scale�?up of direct�?acting antiviral therapies targeting"/>
  <result pre="CullenBL, HutchinsonSJ, et al. Limited impact of awareness�?raising campaigns on" exact="hepatitis" post="C testing practices among general practitioners. J Viral Hepat."/>
  <result pre="57MesquitaF, SantosME, BenzakenA, et al. The Brazilian comprehensive response to" exact="hepatitis" post="C: from strategic thinking to access to interferon�?free therapy."/>
  <result pre="syringe provision and opiate substitution therapy on the incidence of" exact="hepatitis" post="C virus in injecting drug users: pooling of UK"/>
  <result pre="effects of needle�?sharing and opioid substitution therapy on incidence of" exact="hepatitis" post="C virus infection and reinfection in people who inject"/>
  <result pre="65El�?AkelW, El�?SayedMH, El KassasM, et al. National treatment programme of" exact="hepatitis" post="C in Egypt: Hepatitis C virus model of care."/>
  <result pre="J Viral Hepatitis. 2017;24:262�?267. 66AyoubHH, Abu�?RaddadLJ. Impact of treatment on" exact="hepatitis" post="C virus transmission and incidence in Egypt: A case"/>
  <result pre="Hepatol. 2019;4:135�?184.30647010 69LieuJ, LiangW, JingW, LiuM. Countdown to 2030: eliminating" exact="hepatitis" post="B disease, China. Bull World Health Organ. 2019;2019:230�?238. 70LiangX,"/>
  <result pre="71collab: Centers for Disease Control and Prevention . Progress in" exact="hepatitis" post="B prevention through universal infant vaccination–China, 1997–2006. MMWR Morb"/>
  <result pre="Morb Mortal Wkly Rep. 2007;56:441�?445.17495790 72ZhouYH, WuC, ZhuangH. Vaccination against" exact="hepatitis" post="B: the Chinese experience. Chin Med J (Engl). 2009;122:98�?102.19187625"/>
  <result pre="Immunization. Vaccine. 2013;31(Suppl 9):J15�?20.24331015 74HutinY, HennesseyK, CairnsL, et al. Improving" exact="hepatitis" post="B vaccine timely birth dose coverage: lessons from five"/>
  <result pre="https://data.unicef.org/wp-content/uploads/country_profiles/China/immunization_country_profiles/immunization_chn.pdf. 76KandeelA, GenedyM, El�?RefaiS, FunkAL, FontanetA, TalaatM. The prevalence of" exact="hepatitis" post="C virus infection in Egypt 2015: implications for future"/>
  <result pre="current trends and policy recommendations - policy brief (English). Egypt's" exact="viral hepatitis" post="program. Washington, DC: World Bank Group; 2018http://documents.worldbank.org/curated/en/164381517333701631/Eliminating-Hepatitis-Cfrom-Egypt-2017-update-on-current-trends-and-policyrecommendations-policy-brief 78ElsharkawyA, El�?RazikyM,"/>
  <result pre="trends and policy recommendations - policy brief (English). Egypt's viral" exact="hepatitis" post="program. Washington, DC: World Bank Group; 2018http://documents.worldbank.org/curated/en/164381517333701631/Eliminating-Hepatitis-Cfrom-Egypt-2017-update-on-current-trends-and-policyrecommendations-policy-brief 78ElsharkawyA, El�?RazikyM,"/>
  <result pre="Hepatitis Alliance . Nine countries now on track to eliminate" exact="hepatitis" post="C Sao Paolo: World Hepatitis Alliance; 2017 [updated 1"/>
  <result pre="from: http://www.worldhepatitisalliance.org/news/nov-2017/nine-countries-now-track-eliminate-hepatitis-c. 80AssefaY, HillPS, UlikpanA, WilliamsOD. Access to medicines and" exact="hepatitis" post="C in Africa: can tiered pricing and voluntary licencing"/>
  <result pre="81RosenthalES, GrahamCS. Price and affordability of direct�?acting antiviral regimens for" exact="hepatitis" post="C virus in the United States. Infect Agent Cancer."/>
  <result pre="82FitzSimonsD, HendrickxG, HallauerJ, et al. Innovative sources for funding of" exact="viral hepatitis" post="prevention and treatment in low�? and middle�?income countries: a"/>
  <result pre="HendrickxG, HallauerJ, et al. Innovative sources for funding of viral" exact="hepatitis" post="prevention and treatment in low�? and middle�?income countries: a"/>
  <result pre="Med Policy. 2016;1:1630288319 83SutharAB, HarriesAD. A public health approach to" exact="hepatitis" post="c control in low�? and middle�?income countries. PLoS Medicine."/>
  <result pre="countries. PLoS Medicine. 2015;12:e1001795.25757228 84EasterbrookP, JohnsonC, FigueroaC, BaggaleyR. HIV and" exact="hepatitis" post="testing: global progress, challenges, and future directions. AIDS Rev."/>
  <result pre="Virus Erad. 2019;5:60�?66.30800429 86collab: Medicines Patent Pool . Our work:" exact="hepatitis" post="C. 2019 [cited 2019 05 March 2019]; Available from:"/>
  <result pre="et al. Pathways to ensure universal and affordable access to" exact="hepatitis" post="C treatment. BMC Med. 2018;16:175.30296935 88MbituyumuremyiA, Van NuilJI, UmuhireJ,"/>
  <result pre="BMC Med. 2018;16:175.30296935 88MbituyumuremyiA, Van NuilJI, UmuhireJ, et al. Controlling" exact="hepatitis" post="C in Rwanda: a framework for a national response."/>
  <result pre="ThompsonAJ, HellardME. Treatment access is only the first step to" exact="hepatitis" post="C elimination: experience of universal anti�?viral treatment access in"/>
  <result pre="2030. J Hepatol. 2017;67:419�?420.28411042 93collab: The Kirby Institute . Monitoring" exact="hepatitis" post="C treatment uptake in Australia (Issue 8). Sydney, Australia:"/>
  <result pre="Group . Road to elimination: Barriers and best practices in" exact="hepatitis" post="C management. The Boston Consulting Group; 2017 95collab: The"/>
  <result pre="Boston Consulting Group; 2017 95collab: The Kirby Institute . Monitoring" exact="hepatitis" post="C treatment uptake in Australia. Sydney, Australia: UNSW; 2017"/>
  <result pre="et al. Cost�?effectiveness of the controlled temperature chain for the" exact="hepatitis" post="B virus birth dose vaccine in various global settings:"/>
  <result pre="get there?J Int AIDS Soc. 2017;20:1�?11. 98RichmondJA, WallaceJ. Implementation of" exact="hepatitis" post="C cure in Australia: one year on. J Virus"/>
  <result pre="ThurszM. Micro�?elimination &amp;amp; #x2013; A path to global elimination of" exact="hepatitis" post="C. J Hepatol. 2017;67:665�?666.28760329 100SchnierC, WallaceL, TempeltonK, et al."/>
  <result pre="data to estimate the number of people chronically infected with" exact="hepatitis" post="B living in Scotland. Epidemiol Infect. 2014;142:2121�?2130.24480044 101collab: Georgia"/>
  <result pre="Observatory HCV Collaborators . Global prevalence and genotype distribution of" exact="hepatitis" post="C virus infection in 2015: a modelling study. Lancet"/>
  <result pre="ZeuzemS, MannsM, et al. Global prevalence and genotype distribution of" exact="hepatitis" post="C virus infection in 2015: a modelling study. Lancet"/>
  <result pre=". Global policy report on the prevention and control of" exact="viral hepatitis" post="in WHO member states. Geneva, Switzerland: WHO Press, World"/>
  <result pre="Global policy report on the prevention and control of viral" exact="hepatitis" post="in WHO member states. Geneva, Switzerland: WHO Press, World"/>
  <result pre="107collab: World Health Organization . Progress report on access to" exact="hepatitis" post="C treatment: focus on overcoming barriers in low- and"/>
 </snippets>
</snippetsTree>
